1. Functional network connectivity in early-stage schizophrenia.
- Author
-
Hummer TA, Yung MG, Goñi J, Conroy SK, Francis MM, Mehdiyoun NF, and Breier A
- Subjects
- Brain diagnostic imaging, Humans, Magnetic Resonance Imaging, Neural Pathways diagnostic imaging, Brain Mapping, Schizophrenia diagnostic imaging
- Abstract
Schizophrenia is a disorder of altered neural connections resulting in impaired information integration. Whole brain assessment of within- and between-network connections may determine how information processing is disrupted in schizophrenia. Patients with early-stage schizophrenia (n = 56) and a matched control sample (n = 32) underwent resting-state fMRI scans. Gray matter regions were organized into nine distinct functional networks. Functional connectivity was calculated between 278 gray matter regions for each subject. Network connectivity properties were defined by the mean and variance of correlations of all regions. Whole-brain network measures of global efficiency (reflecting overall interconnectedness) and locations of hubs (key regions for communication) were also determined. The control sample had greater connectivity between the following network pairs: somatomotor-limbic, somatomotor-default mode, dorsal attention-default mode, ventral attention-limbic, and ventral attention-default mode. The patient sample had greater variance in interactions between ventral attention network and other functional networks. Illness duration was associated with overall increases in the variability of network connections. The control group had higher global efficiency and more hubs in the cerebellum network, while patient group hubs were more common in visual, frontoparietal, or subcortical networks. Thus, reduced functional connectivity in patients was largely present between distinct networks, rather than within-networks. The implications of these findings for the pathophysiology of schizophrenia are discussed., Competing Interests: Declaration of competing interest The authors report no direct conflicts of interest with this study. AB serves as a consultant for Karuna Pharmaceuticals and BioXcel Therapeutics. NM is currently an employee with Eli Lilly and Company. During data collection and analysis, she was employed by the Indiana University School of Medicine, where she maintains an affiliation., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF